The Sheffield rheumatoid arthritis health economic model

Rheumatology

Volumn 50, Issue SUPPL. 4, 2011, Pages

  Tosh, Jonathan ^a   Brennan, Alan ^a   Wailoo, Allan ^a   Bansback, Nick ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Biologics; Cost; DMARDs; Economic; Effectiveness; Model; Rheumatoid arthritis; Sheffield; Simulation

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AGE; ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; DISEASE DURATION; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; GENDER; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; JOINT PROSTHESIS; MEDICAL HISTORY; MEDICARE; MONOTHERAPY; MONTE CARLO METHOD; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SHORT FORM 36; TEACHING; TREATMENT RESPONSE; UNITED KINGDOM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COST-BENEFIT ANALYSIS; ENGLAND; HEALTH CARE COSTS; HEALTH POLICY; HUMANS; MODELS, ECONOMIC; QUALITY OF LIFE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80052237180     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker243     Document Type: Article

References (22)

1. Weinstein MC, Stason WB. Foundations of costeffectiveness analysis for health and medical practices. New Engl J Med 1977;296:716-21.
2. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. New York: Oxford University Press, 2005.
3. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2004.
4. Brennan A, Akehurst R. Modeling in health economic evaluation. Pharmacoeconomics 2000;17:445-59.
5. Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006;15:1295-310.
6. Bansback N, Ara R, Karnon J, Anis A. Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health states. Pharmacoeconomics 2008; 26:395-408.
7. Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 2004; 43:62-72.
8. Brennan A, Bansback N, Nixon R et al. Modelling the cost effectiveness of TNF-a antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology 2007;46: 1345-54.
9. Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F. Biologic drugs for rheumatoid arthritis in the medicare program: a cost effectiveness analysis. Arthritis Rheum 2008;58:939-46.
10. Deighton C, O'Mahony R, Tosh J, Turner C, Rudolf M. Management of rheumatoid arthritis: summary of NICE guidance. Br Med J 2009;338:b702, doi:10.1136/bmj.b702.
11. National Institute for Health and Clinical Excellence. Rheumatoid arthritis: National Clinical Guideline for management and treatment in adults. London: Royal College of Physicians, 2009.
12. Tosh JC, Wailoo AJ, Scott DL, Deighton CM. Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis. J Rheumatol. Advance Access published May 15, 2011.
13. Fleurence R, Spackman E. Cost-effectiveness of biologic agents for treatment of autoimmune disorders: structured review of the literature. J Rheumatol 2006;33:2124.
14. Barbieri M, Drummond MF, Junoy P et al. Critical appraisal of pharmacoeconomic studies comparing TNF-antagonists for rheumatoid arthritis treatment. Expert Rev Pharmacoecon Outcomes Res 2007;7:613-26.
15. Brown JB, Palmer AJ, Bisgaard P, Chan W, Pedula K, Russell A. The Mt. Hood challenge: cross-testing two diabetes simulation models. Diabetes Res Clin Pract 2000; 50:S57-64.
16. Mount H. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007;30:1638.
17. Berry DA, Cronin KA, Plevritis SK et al. Effect of screening and adjuvant therapy on mortality from breast cancer. New Engl J Med 2005;353:1784.
18. Griffin S, Claxton K, Hawkins N, Sculpher M. Probabilistic analysis and computationally expensive models: necessary and required? Value Health 2006;9: 244-52.
19. Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumour necrosis factor {alpha} and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology 2007;46:1140-7.
20. Nixon RM, Bansback N, Brennan A. Using mixed treatment comparisons and meta regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Stat Med 2007;26:1237-54.
21. Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005;64:995.
22. Nixon RM, O'Hagan A, Oakley J et al. The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation. Pharma Stat 2009;8: 371-89.